The DOI matches its Crossref record; 1,300 of the 1,300 references it cites were found in a registry or an index.
Metal Drugs and the Anticancer Immune Response
Open accessAbstract
The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clinical settings. This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects. It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses. Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment. On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Chattopadhyay, S., Dash, S. K., Mahapatra, S. K., Tripathy, S., Ghosh, T., Das, B., Das, D., Pramanik, P., & Roy, S. (2014) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1085-2 · Cited by 50
RetractedChatterjee, S., Mookerjee, A., Basu, J. M., Chakraborty, P., Ganguly, A., Adhikary, A., Mukhopadhyay, D., Ganguli, S., Banerjee, R., Ashraf, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007048 · Cited by 46
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997) · Nature · doi:10.1038/39807 · Cited by 9,107
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Host-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Inflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Mechanism and medical implications of mammalian autophagy
Dikic, I., & Elazar, Z. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0003-4 · Cited by 2,771
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Levy, J. M. M., Towers, C. G., & Thorburn, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.53 · Cited by 2,526
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1)
Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T., & Tada, K. (1980) · International Journal of Cancer · doi:10.1002/ijc.2910260208 · Cited by 2,254
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Decoding the Patterns of Self and Nonself by the Innate Immune System
Medzhitov, R., & Janeway, C. A. (2002) · Science · doi:10.1126/science.1068883 · Cited by 2,154
Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway
Otterbein, L. E., Bach, F. H., Alam, J., Soares, M., Tao Lu, H., Wysk, M., Davis, R. J., Flavell, R. A., & Choi, A. M. K. (2000) · Nature Medicine · doi:10.1038/74680 · Cited by 2,153
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,767
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745
How dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
The side effects of platinum-based chemotherapy drugs: a review for chemists
Oun, R., Moussa, Y. E., & Wheate, N. J. (2018) · Dalton Transactions · doi:10.1039/c8dt00838h · Cited by 1,737
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Deconvoluting the context-dependent role for autophagy in cancer
White, E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3262 · Cited by 1,704
Diversity of structures and properties among catalases
Chelikani, P., Fita, I., & Loewen, P. C. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3206-5 · Cited by 1,700
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in Tumor Research · doi:10.1159/000386035 · Cited by 1,656
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
The therapeutic potential of carbon monoxide
Motterlini, R., & Otterbein, L. E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3228 · Cited by 1,638
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Smyth, E. C., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw350 · Cited by 1,555
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014) · Cancers · doi:10.3390/cancers6031670 · Cited by 1,538
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., Oldenborg, P.-A., Michalak, M., & Henson, P. M. (2005) · Cell · doi:10.1016/j.cell.2005.08.032 · Cited by 1,473
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
B lymphocytes: how they develop and function
LeBien, T. W., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-02-078071 · Cited by 1,400
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Crans, D. C., Smee, J. J., Gaidamauskas, E., & Yang, L. (2004) · Chemical Reviews · doi:10.1021/cr020607t · Cited by 1,364
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
New trends for metal complexes with anticancer activity
Bruijnincx, P. C., & Sadler, P. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.11.013 · Cited by 1,306
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31257-1 · Cited by 1,296
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
The P2X7 Receptor in Infection and Inflammation
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L., & Falzoni, S. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.020 · Cited by 1,267
PAMP s and DAMP s: signal 0s that spur autophagy and immunity
Tang, D., Kang, R., Coyne, C. B., Zeh, H. J., & Lotze, M. T. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01146.x · Cited by 1,221
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms
Beyersmann, D., & Hartwig, A. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0313-y · Cited by 1,206
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Function and Mechanism of Zinc Metalloenzymes
McCall, K. A., Huang, C.-C., & Fierke, C. A. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.5.1437s · Cited by 1,136
Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis
Chekeni, F. B., Elliott, M. R., Sandilos, J. K., Walk, S. F., Kinchen, J. M., Lazarowski, E. R., Armstrong, A. J., Penuela, S., Laird, D. W., Salvesen, G. S., et al. (2010) · Nature · doi:10.1038/nature09413 · Cited by 1,120
Pharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
Mima, K., Nishihara, R., Qian, Z. R., Cao, Y., Sukawa, Y., Nowak, J. A., Yang, J., Dou, R., Masugi, Y., Song, M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310101 · Cited by 1,080
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
Gold nanoparticles as novel agents for cancer therapy
Jain, S., Hirst, D. G., & O'Sullivan, J. M. (2012) · The British Journal of Radiology · doi:10.1259/bjr/59448833 · Cited by 1,059
Galli, S. J., Borregaard, N., & Wynn, T. A. (2011) · Nature Immunology · doi:10.1038/ni.2109 · Cited by 1,055
Cobalt toxicity in humans—A review of the potential sources and systemic health effects
Leyssens, L., Vinck, B., Van Der Straeten, C., Wuyts, F., & Maes, L. (2017) · Toxicology · doi:10.1016/j.tox.2017.05.015 · Cited by 1,045
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Apoptosis: The Biochemistry and Molecular Biology of Programmed Cell Death*
SCHWARTZMAN, R. A., & CIDLOWSKI, J. A. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-2-133 · Cited by 1,040
Elevated copper and oxidative stress in cancer cells as a target for cancer treatment
Gupte, A., & Mumper, R. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.07.004 · Cited by 1,036
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Shaw, C. F. (1999) · Chemical Reviews · doi:10.1021/cr980431o · Cited by 990
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
Mechanisms of action of arsenic trioxide.
Miller, W. H., Schipper, H. M., Lee, J. S., Singer, J. W., & Waxman, S. (2002) · PubMed · Cited by 956
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Gut microorganisms, mammalian metabolism and personalized health care
Nicholson, J. K., Holmes, E., & Wilson, I. D. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1152 · Cited by 945
The intestinal epithelium: central coordinator of mucosal immunity
Allaire, J. M., Crowley, S. M., Law, H. T., Chang, S.-Y., Ko, H.-J., & Vallance, B. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.002 · Cited by 933
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Arsenic and human health effects: A review
Mohammed Abdul, K. S., Jayasinghe, S. S., Chandana, E. P. S., Jayasumana, C., & De Silva, P. M. C. S. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2015.09.016 · Cited by 907
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Cytokine patterns in patients with cancer: a systematic review
Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 905
Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15606 · Cited by 866
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Chen, G., Zhu, J., Shi, X., Ni, J., Zhong, H., Si, G., Jin, X., Tang, W., Li, X., Xong, S., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1052.1052 · Cited by 864
Regulatory T cells: how do they suppress immune responses?
Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P., & Yamaguchi, T. (2009) · International Immunology · doi:10.1093/intimm/dxp095 · Cited by 854
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Self-citationMechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00541h · Cited by 830
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Self-citationPresent yourself! by MHC class I and MHC class II molecules
Rock, K. L., Reits, E., & Neefjes, J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.010 · Cited by 814
Targeting copper in cancer therapy: ‘Copper That Cancer’
Denoyer, D., Masaldan, S., La Fontaine, S., & Cater, M. A. (2015) · Metallomics · doi:10.1039/c5mt00149h · Cited by 806
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 779
Modulation of the antitumor immune response by complement
Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., & Lambris, J. D. (2008) · Nature Immunology · doi:10.1038/ni.1655 · Cited by 778
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans
P.B. Danielson, B. S. P. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 772
Hume, D. A., & MacDonald, K. P. A. (2012) · Blood · doi:10.1182/blood-2011-09-379214 · Cited by 763
Apoptosis and cancer: the genesis of a research field
Cotter, T. G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2663 · Cited by 758
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release
Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D. J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120189 · Cited by 720
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.014 · Cited by 715
Tumor-Associated Neutrophils: New Targets for Cancer Therapy
Gregory, A. D., & McGarry Houghton, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2583 · Cited by 707
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215606 · Cited by 707
Regulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Smith, S. M., Le Beau, M. M., Huo, D., Karrison, T., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 682
Schiraldi, M., Raucci, A., Muñoz, L. M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111739 · Cited by 676
Tyrosine Phosphorylation of IκB-α Activates NF-κB without Proteolytic Degradation of IκB-α
Imbert, V., Rupec, R. A., Livolsi, A., Pahl, H. L., Traenckner, E. B.-M., Mueller-Dieckmann, C., Farahifar, D., Rossi, B., Auberger, P., Baeuerle, P. A., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80153-1 · Cited by 660
The multifaceted role of CD4+ T cells in CD8+ T cell memory
Laidlaw, B. J., Craft, J. E., & Kaech, S. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.10 · Cited by 657
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Starobova, H., & Vetter, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00174 · Cited by 648
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
The function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Research works printed but not linked: 47
- van der Most R. G., 2005, Discovery Medicine, 5, 265
- Alberts B., 2015, Mol. Biol. Cell
- Seliger B., 1996, Exp. Hematol., 24, 1275
- Fink D., 1996, Cancer Res., 56, 4881
- Yoshikawa A., 1997, Kobe J. Med. Sci., 43, 109
- 10.1007/s00775-018- 1546-8 · doi:10.1007/s00775-018-
- Rosenberg, B. In Advances in Antimicrobial and Antineoplastic Chemotherapy, University Park Press: Baltimore, 1972; Vol. 11.
- 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X · doi:10.1002/(sici)1098-2264(199704)18:4<286::aid-gcc6>3.0.co;2-x
- Dempsey J. L., 1985, Cancer Res., 45, 2873
- Nio Y., 2000, Anticancer Res., 20, 3293
- Qin X., 2010, Cell. Mol. Biol. (Noisy- le-grand), 56, 1366
- Kleinerman E. S., 1980, Cancer Res., 40, 3099
- Lichtenstein A. K., 1986, Cancer Res., 46, 639
- 10.1002/1097-0142(19930215)71:4<1313::AID-CNCR2820710424>3.0.CO;2-# · doi:10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#
- Yamaue H., 1991, J. Clin. Lab. Immunol., 35, 165
- 10.1002/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A · doi:10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a
- Jiang J., 2006, Anticancer Res., 26, 2237
- Ujiie T., 1989, Jpn. J. Exp. Med., 59, 17
- Maeda K., 2011, Anticancer Res., 31, 4569
- Miller W. H., 2002, Cancer Res., 62, 3893
- 10.1097/CJI.0b013e3181755deb · DOI
- Kreuser E. D., 1992, Semin. Oncol., 19, 73
- Magnarin M., 2000, Anticancer Res., 20, 2939
- Nardon C., 2014, Anticancer Res., 34, 487
- Hashimoto K., 1994, J. Rheumatol., 21, 1020
- Yan A., 1990, J. Rheumatol., 17, 47
- Wang X. D., 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 533
- 10.1371/journal.pone.0100933 · DOI
- Korbecki J., 2012, Acta Biochim. Polym., 59, 195
- 10.3109/1547691X.2014.996681 · DOI
- Desoize B., 2004, Anticancer Res., 24, 1529
- Sava G., 1985, Anticancer Res., 5, 249
- Boscolo P., 2004, Ann. Clin. Lab. Sci., 34, 299
- Brewer G. J., 2000, Clin. Cancer Res., 6, 1
- Redman B. G., 2003, Clin. Cancer Res., 9, 1666
- Pan Q., 2003, Mol. Cancer Res., 1, 701
- Lukasewycz O. A., 1982, J. Natl. Cancer Inst., 69, 489
- 10.1515/9783110470734-016 · doi:10.1515/9783110470734-016
- Eriksson M., 2009, Anticancer Res., 29, 11
- Signat B., 2011, Curr. Issues Mol. Biol., 13, 25
- Sonis S. T., 2004, J. Support. Oncol., 2, 21
- 10.1053/sonc.2002.35524 · doi:10.1053/sonc.2002.35524 · Paper page
- Juhn S. K., 2001, Int. Tinnitus J., 7, 72
- Boussios S., 2012, Ann. Gastroenterol., 25, 106
- Takeyama K., 2000, Int. J. Hematol., 71, 144
- Giles F. J., 1994, Curr. Opin. Hematol., 1, 256
- Lu J., 2017, Ochsner J., 17, 379
Cited by
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Toxicity of gold nanoparticles (AuNPs): A review
Sani, A., Cao, C., & Cui, D. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.100991 · Cited by 454
Classification of Metal-Based Drugs according to Their Mechanisms of Action
Boros, E., Dyson, P. J., & Gasser, G. (2020) · Chem · doi:10.1016/j.chempr.2019.10.013 · Cited by 437
New Designs for Phototherapeutic Transition Metal Complexes
Imberti, C., Zhang, P., Huang, H., & Sadler, P. J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201905171 · Cited by 443
The immune microenvironment in cartilage injury and repair
Li, M., Yin, H., Yan, Z., Li, H., Wu, J., Wang, Y., Wei, F., Tian, G., Ning, C., Li, H., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.12.006 · Cited by 403
Metadata
- Authors
- Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- University of Vienna (AT)
- Corresponding author
- Berger, Walter
- ORCID
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-29
- Volume
- 119
- Issue
- 2
- Pages
- 1519-1624
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2903051221
- Cited by
- 355
- References
- 1,298
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 47 · 2023: 51 · 2022: 49 · 2021: 45 · 2020: 53 · 2019: 38
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- FP7 People: Marie-Curie Actions (609431)
- Universit?t Wien
- Medizinische Universit?t Wien
- Johanna Mahlke, geb. Obermann-Stiftung zur F?rderung der Krebsforschung an der Universit?t Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- metal-based anticancer agents, antitumor immunity, immune surveillance, immune evasion, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, innate and adaptive immunity
- MeSH terms
- Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Immunity, Innate, Immunotherapy, Lymphocytes, Metals, Neoplasms, Nanoparticles, Coordination Complexes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.